Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average […]
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average […]
